Eli

Eli Lilly (LLY) has secured Chinese regulatory approval for its oral GLP-1 weight-loss drug, orforglipron, becoming the first drugmaker to receive clearance for a GLP-1 weight-loss pill in the country, Reuters reported, citing China’s medicine regulator.

The approval gives Eli

Eli Lilly’s revenue growth is mainly due to its weight-loss and obesity franchise, blockbuster drugs like Mounjaro, Zepbound, and new developments such as the oral GLP-1 drug Foundayo and the pipeline drug Retatrutide, which drives significant investor focus.